Biotech Values

[xavierprivas]

Vascepa was approved in 2013 for lowering triglycerides in patients with
severe (≥500 mg/dL) hypertriglyceridemia.
It is a small market and AMRN stock and revenue languish for a long time.
Acasti is also after the same market so there is nothing to get excited
about even if their drug is better.

Unless Acasti conducts a similar study to AMRN REDUCE-IT trial that lowers
the risk of cardiovascular disease which is a huge market, they will suffer the same fate.
In the REDUCE-IT patients were followed up for an average of 4.9 years.

https://www.nejm.org/doi/full/10.1056/NEJMoa1812792

It would be a long time plus a lot of money for Ascati, first to get
approval for hypertriglyceridemia and to beat AMRN at reducing CV risk in
another trial similar to REDUCE-IT.